^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    TYK2 inhibitor

    Associations

    News

    Trials
    2d
    COMBo: Deucravacitinib-TNF Combination Therapy for Difficult-to-Control Psoriatic Disease (clinicaltrials.gov)
    P4, N=128, Not yet recruiting, University of Texas Southwestern Medical Center
    New P4 trial
    4d
    An Investigational Study of ESK-001 in Participants With Normal Renal Function and Participants With Mild, Moderate, and Severe Impaired Renal Function (clinicaltrials.gov)
    P1, N=16, Completed, Alumis Inc | Recruiting --> Completed | N=48 --> 16 | Trial completion date: Dec 2025 --> Aug 2025 | Trial primary completion date: Dec 2025 --> Aug 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    5d
    Evaluate the Efficacy and Safety of D-2570 in Subjects With Moderate to Severe Plaque Psoriasis (clinicaltrials.gov)
    P3, N=390, Recruiting, InventisBio Co., Ltd | Not yet recruiting --> Recruiting
    Enrollment open
    6d
    Healthy Volunteer Study (clinicaltrials.gov)
    P1, N=36, Recruiting, InventisBio Co., Ltd
    New P1 trial
    11d
    POETYK SLE-1: A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE) (clinicaltrials.gov)
    P3, N=516, Active, not recruiting, Bristol-Myers Squibb | Recruiting --> Active, not recruiting | Trial completion date: Dec 2027 --> Nov 2028 | Trial primary completion date: Dec 2025 --> Oct 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    12d
    POETYK SLE-2: A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (clinicaltrials.gov)
    P3, N=513, Active, not recruiting, Bristol-Myers Squibb | Recruiting --> Active, not recruiting | Trial completion date: Dec 2027 --> Nov 2028 | Trial primary completion date: Dec 2025 --> Oct 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    13d
    Deucravacitinib for Patients With Moderate/Severe Psoriasis: A Real-Life Experience in Italy (clinicaltrials.gov)
    P=N/A, N=200, Recruiting, Bristol-Myers Squibb
    New trial
    18d
    A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis (clinicaltrials.gov)
    P3, N=110, Not yet recruiting, Takeda
    New P3 trial
    18d
    Efficacy and Safety of ICP-332 Versus Placebo in Participants With Moderate to Severe Plaque Psoriasis (clinicaltrials.gov)
    P2, N=172, Not yet recruiting, Beijing InnoCare Pharma Tech Co., Ltd.
    New P2 trial
    20d
    Study of Deucravacitinib for Refractory Adults With Dermatomyositis/Juvenile Dermatomyositis (clinicaltrials.gov)
    P2, N=0, Withdrawn, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | N=20 --> 0 | Trial completion date: Mar 2029 --> Nov 2025 | Not yet recruiting --> Withdrawn | Trial primary completion date: Mar 2028 --> Nov 2025
    Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date
    |
    TYK2 (Tyrosine Kinase 2)
    20d
    A Study of Zasocitinib in Adults With Hidradenitis Suppurativa (clinicaltrials.gov)
    P2, N=90, Not yet recruiting, Takeda
    New P2 trial
    24d
    TAK-279-3002: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period (clinicaltrials.gov)
    P3, N=1108, Completed, Takeda | Active, not recruiting --> Completed
    Trial completion